The 4 T’s of ITP: Tailoring Therapies to Treat Thrombocytopenia
David Hughes, PharmD, BCOP
From Boston University School of Medicine, Boston, Massachusetts
Presenter’s disclosure of conflicts of interest is found at the end of this article.
J Adv Pract Oncol 2022;13(3):337–340 |
© 2022 Harborside™
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting.
For access to the full length article, please sign in